FDA May Refuse Imports of Drugs from Canada-Based CMI Cosmetic
The Food and Drug Administration may refuse admission of imports of pharmaceuticals from Canada-based CMI Cosmetic Manufacturers, the agency said in a warning letter dated April 25. According to the letter, a recent FDA inspection found violations of current good…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
manufacturing practice requirements at the Concord, Ontario facility. The company also failed to register with FDA, but still offered its pharmaceuticals for import into the U.S., the agency said.